Outcome is better in patients with idiopathic dilated cardiomyopathy (IDC) than in ischemic heart failure (HF), but morbidity and mortality are nevertheless presumed to be substantial. Most data on the prognosis in IDC stem from research performed prior to the widespread use of current evidence based treatment, including implantable devices. We report outcome data from a cohort of patients with IDC treated according to current HF guidelines and compare our results with previous figures: 102 consecutive patients referred to our tertiary care hospital with idiopathic IDC and a left ventricular ejection fraction (LVEF) < 40 % were included in a prospective cohort study. After extensive baseline work-up, follow-up was performed after 6 and 13 months. Vital status and heart transplantation were recorded. Over the first year of follow-up, the patients were on optimal pharmacological treatment, and 24 patients received implantable devices. LVEF increased from 26 ± 10 % to 41 ± 11 %, peak oxygen consumption increased from 19.5 ± 7.1 to 23.4 ± 7.8 ml/kg/min, and functional class improved substantially (all p-values < 0.001). After a median follow up of 3.6 years, 4 patients were dead, and heart transplantations had been performed in 9 patients. According to our literature search, there survival in patients with IDC has improved substantially over the last decades. In conclusion, patients with IDC have a better outcome than previously reported when treated according to current guidelines.
Approximately 50 % of people diagnosed with HF die within 5 years. 1 The outcome is strongly related to left ventricular (LV) function. 2, 3 Approximately 10 % of HF cases are due to idiopathic dilated cardiomyopathy (IDC). 4 Its prognosis is generally better than in patients with ischemic HF. 5, 6 The 5-year mortality is substantial, however, ranging from > 50 % in early accounts 7 to approximately 25 % in more recent reports. 6, 8 Reported survival varies due to different inclusion criteria in different trials. In addition, there has probably been a real improvement in outcome as treatment for HF has advanced over the last 3 decades. 9 A number of studies have shown that LV function often improves considerably in patients recently diagnosed with IDC. 3, [10] [11] [12] The reason for this improvement, which is beyond what is observed after the initiation of treatment in patients with HF of ischemic etiology, 11, 13 is poorly understood. Also, this improvement is by no means uniform and can be difficult to predict. We present outcome data from a contemporary cohort of patients with IDC treated according to current guidelines. 14 We hypothesized that in a meticulously assessed and well treated, contemporary cohort of patients with IDC, LV reverse remodeling and functional improvement would be substantial, and that the long-term prognosis would compare favorably with what has been reported previously.
METHODS
This is a prospective cohort study performed at our tertiary care university hospital. The trial complies with the Declaration of Helsinki and was approved by the Regional Committee for Medical and Health Research Ethics South East. The results are reported according to the STROBE guidelines. All patients provided written, informed consent.
Patients aged 18 or above, admitted to our cardiology department with suspected IDC, were eligible for participation. Inclusion criteria were a dilated left ventricle (end diastolic internal diameter ≥ 6.5 cm or an indexed value of > 3.2 cm/m 2 ), and a left ventricular ejection fraction (LVEF) ≤ 40 %. Ischemic, hypertensive and primary valvular heart disease were excluded by patient history, clinical examination, echocardiography, and coronary angiography (N = 101) or computer tomography angiography (N = 1) prior to inclusion. Other exclusion criteria were: A known or suspected cause of cardiomyopathy, including acute or prior myocarditis; inotropic or mechanical support at admittance; an implantable cardiac device (pacemaker, intra cardiac defibrillator and/or biventricular pacemaker); and significant concomitant disease such as chronic infections, connective tissue disease, severe pulmonary disease, cancer, serious psychiatric disease, life threatening ventricular arrhythmias, severe kidney failure or severe hepatic failure. As we are the only center in Norway to perform orthotopic heart transplantation, patients referred specifically for heart transplant evaluation were excluded to avoid outcome selection bias. Patients who were referred for diagnostic work-up, and were later found to be in need of heart transplantation, were not excluded. Atrial fibrillation was not an exclusion criterion, provided the ventricular rate had been well controlled (i.e an average resting heart rate < 100 beats per minute) over the last 4 weeks. As we are a tertiary care hospital, all patients had been admitted to their local hospitals initially, and unless the patients were in need of immediate mechanical support or urgent evaluation for heart transplantation, we usually awaited the effect of pharmacological intervention before the patients were transferred to our centre.
At baseline, the study participants underwent physical examination; blood tests including screening for known monogenic causes of IDC; echocardiography; cardiac magnetic resonance imaging (CMR); exercise testing with measurement of peak oxygen uptake; 24-hour electrocardiogram (ECG); and right-sided cardiac catheterization with endomyocardial biopsy. Follow-up was performed after 6 months and 1 year. Patients were later followed through the Norwegian National Population Register and our national heart transplant database for mortality and heart transplantation, respectively. Patient records were acquired from local hospitals for adjudication of events.
Echocardiography was performed with Vivid 7 or E9 ultrasound scanners (GE Vingmed Ultrasound, Horten, Norway), using phased array transducers. Three heart beats were recorded for each registration. Cine loops were digitally stored and later analyzed off-line using Echo-Pac (GE Vingmed Ultrasound). Individual exams were de-identified and randomized, and image analysis was performed blinded to patient characteristics and to whether the exam was performed at baseline or follow-up. Two-dimensional parameters and conventional Doppler parameters were measured according to current recommendations. 15, 16 Left ventricular ejection fraction was measured by Simpson's biplane method.
Exercise testing was performed on a bicycle ergo meter using an individualized, stepwise protocol, with the load incrementally increased every minute. Associations between baseline parameters and 1) the LVEF and 2) the age and gender adjusted peak oxygen consumption at one year follow-up were assessed by univariate and multiple linear regression. Skewed parameters were log-transformed prior to regression analyses. To avoid over-fitting, rather than feeding a large number of potential risk factors into an automated statistical algorithm, we a priori selected risk factors which have previously been shown to be associated with outcome in HF (age; symptom severity; duration of symptoms; heart rate and rhythm; blood pressure; LV volume and ejection fraction; peak oxygen consumption; QRS-width; pulmonary capillary wedge pressure and N-terminal-pro-B-type natriuretic peptide [NT-proBNP]). Associations between baseline values and the time to death due to HF or heart transplantation were assessed by Cox regression. P-values < 0.05 were considered significant. All statistical analyses were performed in SPSS version 21.0.
We performed a PubMed search using the search string [(dilated cardiomyopathy) and (mortality or survival) and (cohort studies or cohort or longitudinal or follow-up or "follow up" or prospective or retrospective)], and restricted our search to reports in English concerning adult, human patients. In addition, we used "snowballing" to identify additional reports pertaining to mortality in IDC. Patients screened for participation (n = 265) 163 patients excluded due to Referral specifically for heart transplant evaluation (n = 36) Ischemic heart failure (n = 9) LVEF above 40 % or left ventricular internal diameter below 6.5 cm / 3.3 cm/m 2 (n = 29) On mechanical or inotropic support (n = 17) Primary valvular heart disease (n = 8) Known or suspected cause of dilated cardiomyopathy* (n = 37) Intra cardiac device (n = 54) Reduced life expectancy due to non-cardiac disease (n = 7) Not included for administrative reasons (n = 5) Unwilling to participate (n = 3) Compliance deemed poor (n = 12)
Included (n = 102)
Transplanted or on LVAD (n = 3)
Lost to short term follow-up (n = 2) Follow-up after 13 months (n = 95) Transplanted (n = 6), dead due to worsening heart failure (n = 2), dead due to other reasons (n = 2) Alive and transplantfree after a median follow-up of 3.5 (2.2 -
4.4) years (n = 89)
Follow-up after 6 months (n = 97)
Lost to short term follow-up (n = 4)
RESULTS
Patient recruitment and follow-up are summarized in Figure 1 . From the 13 th of October 2008 to the 16 th of November 2012, a total of 265 consecutive patients were evaluated for participation. One hundred and fifty five patients did not fulfill the inclusion criteria, 3 patients were unwilling to participate, and 5 patients were not included for administrative reasons. One hundred and two patients were thus included in the current study. Their baseline data are presented in Table 1 . Table 2 . By design, no patients had implantable devices at inclusion. Table 2 : Treatment during first year of follow-up *Left ventricular assist devices were used as bridge to transplantation.
At 6 months' follow-up, 97 patients were re-examined. One patient was on an LV assist device awaiting heart transplantation, 2 patients had received cardiac allografts, and 2 patients did not appear for their scheduled appointments. At 13 (12-16) months, 95 patients were re-examined: In addition to the 3 heart transplant recipients, 4 patients did not appear for their appointments. One of these patients did not show up for either of the 2 scheduled follow-up appointments and was thus lost to short-term follow-up (Figure 1 ).
Prior to treatment initiation, the large majority of patients were severely symptomatic. During follow-up, there was a highly significant change in NYHA classification over-all (χ 2 [3] = 200.7; p < 0.001), most of which occurred shortly after treatment initiation (Figure 2 ). A substantial increase in LVEF was observed in transplant-free survivors throughout the first year of follow-up (Table 3 and Figure 3 ). From baseline to 13 months, 69 patients experienced an increase in LVEF by ≥ 5 percentage points, 7 patients had a decrease in LVEF by ≥ 5 percentage points, and in 19 patients, there was no change (between -5 and 5 percentage points change). After 13 months, 22 patients (22 %) had achieved complete LV recovery, defined as an LVEF > 50 %, 11 of whom also had a normal NT-proBNP value at this time point. Most of the improvement in LVEF took place shortly after presentation, and after 6 months, it had increased to 37 ± 9 %. On univariate analyses, the duration of symptoms prior to inclusion; QRS-width; and LV end diastolic volume on presentation were associated with LVEF 1 year later. Left ventricular ejection fraction at baseline was not associated with LVEF at follow-up. Only LV end diastolic volume and the duration of symptoms on presentation remained independent predictors of 1 year LVEF in the multivariate model ( Table 4 ). The duration of symptoms in patients who recovered by more than 10 LVEF points was 5 (2 -8) months vs 12 (7 -35) months in patients who did not recover (p < 0.001). Of note, neither viral persistence as examined by polymerase chain reaction in myocardial biopsies (p = 0.63), a monogenic etiology (p = 0.44), nor Gadolinium late enhancement (p = 0.82) at baseline were associated with LVEF at follow-up.
Table 3: Changes in key parameters over the first year of follow-up
Values are presented as mean ± standard deviation or median (interquartile range) depending on the distribution. *This column contains the population average change and the 95 % confidence interval of this mean. † These confidence intervals were estimated by bootstrapping.
During the first 13 months, peak oxygen uptake in transplant free survivors increased by more than 1 metabolic unit (Table 3 and Figure  3) . Parameters reflecting the severity of HF were associated with peak oxygen consumption at baseline as well as at followup. Peak oxygen consumption at follow-up correlated strongly with peak oxygen consumption at baseline (r = 0.67, p < 0.001), but was only weakly correlated with other baseline parameters (data not shown). The improvement in peak oxygen consumption from baseline to follow-up was associated with the improvement in LVEF (r = 0.45; p < 0.001). After a median of 3.5 (2.2 -4.4) years followup, 4 patients were dead. Two patients died from worsening HF, 1 died from a traumatic subdural hematoma, and 1 patient died a sudden, unexplained death more than 3 years after inclusion. Nine patients had received cardiac allografts, 1 of whom later died from acute allograft rejection. Overall survival at 5 years was 93 %, and transplant-free survival was 84 % (Supplementary figure 1) . The number of deaths and heart transplantations was too limited to allow for reliable multiple variable analyses. However, the 11 patients who died due to worsening HF or needed heart transplantation had on average more severe symptoms and more advanced HF at baseline. Compared with transplant-free survivors, they were on average younger (age at inclusion 41 vs 53 years; p = 0.005); their baseline LVEF was lower (18 vs. 28 %; p < 0.001); their pulmonary capillary wedge pressure was higher (25 vs. 14 mm Hg; p < 0.001); their relative exercise capacity was lower (50 vs. 71 % of the age and gender adjusted expected value; p = 0.004) and their systolic blood pressure was lower (103 vs. 118 mm Hg; p = 0.02). The differences in the change in left ventricular ejection fraction across groups were analyzed using ANOVA.
The PubMed search produced 1052 hits as of Jan 7 th 2015. Among these reports, we identified 176 reports including > 50 patients with IDC who had been followed for > 1 year, and where survival data were reported, or studies with a mixed population of patients with HF where survival data for the subset of patients with IDC were reported specifically.
Inclusion criteria, population characteristics, follow-up time and the way the survival data were presented varied considerably, making direct comparison difficult. Overall, there was a strong trend towards improved outcome with time. In Table 5 , we have listed 2 representative reports from each of the last decades for comparison with our own results. Table 5 : Survival in patients with dilated cardiomyopathy *70 % in the 411 patients not receiving β-receptor antagonists at the beginning of the study, and 87 % in patients receiving β-receptor antagonists. †Number of patients in the Sudden Cardiac Death in Heart Failure (SCDHeFT) trial with non-ischaemic heart failure.
‡ Five year survival 72 % in patients assigned to optimal pharmacological treatment + placebo, and 79 % in patients assigned to optimal medical therapy + ICD. ¶ The 5 year transplant-free survival in our patients was 84 %. 
DISCUSSION
In our cohort of patients with IDC, considerable improvements in LVEF, functional status and peak oxygen consumption were observed over the first year of follow-up. Most of this improvement in occurred soon after the onset of therapy. Transplant free survival after a median of 3.5 years of followup was higher than previously reported. These results must be interpreted against a background of a relatively short median duration of symptoms, a thorough diagnostic evaluation, tailored treatment and a high level of adherence to current treatment guidelines.
In most patients, a substantial LV reverse remodeling took place, with an average 30 % reduction in LV end diastolic volume and a 13 percentage points' increase in LVEF. A short duration of symptoms and a relatively small LV size on presentation were independently associated with a favorable LV function at follow-up. These parameters are indicators of short disease duration. Possibly, these variables are also surrogate markers of an acute, at least partly reversible, pathogenic process. However, despite an extensive baseline work-up, a definitive diagnosis was made in a limited number of patients only, none of whom had primary myocarditis. Moreover, we found that even in patients with a probable monogenic (and thus presumably non-reversible) etiology, the LVEF improved considerably. It is therefore possible that other, co-pathogenic factors are at play that can be partly reversed in recently symptomatic dilated cardiomyopathy, irrespective of the etiology.
Whereas an irreversible loss of myocardial tissue lies at the core of the pathogenesis in ischemic HF, the myocardium is not necessarily irretrievably damaged in IDC. Therefore, patients with IDC might retain a potential for almost complete recovery, given that the drivers of the pathogenic processes can be reversed, be it through spontaneous improvement or optimal therapy. Our patients received optimal treatment as evident from the high adherence to recommended pharmacological treatment and the high number of implanted devices.
The term "myocardial recovery" has been coined to denote the normalization of LV structure and function and the freedom from future HF events. 23 Twenty-two percent of our patients experienced myocardial remission defined as an LVEF > 50 %. However, NTproBNP remained above our laboratory reference values in half of these patients, meaning that only 11 patients had a normal cardiac function 13 months after inclusion. Incidentally, 2 of these patients subsequently died, 1 suddenly and unexplained, and 1 from worsening HF. Thus, the normalization of LV systolic function in patients with IDC does not necessarily signify the absence of pathology, 24 and we do not recommend cessation of medical therapy in patients with myocardial remission.
Prognosis in HF is linked to LV size and function, 2, 25, 26 and reverse remodeling is associated with a favorable outcome. [27] [28] [29] In accordance with the substantial increase in LVEF that we observed over the first year of follow-up, the transplant free and overall survival in our patients was fair, and better than previously described. There are many possible explanations for this. The referral practice to tertiary centers may have become more liberal with time, which might influence the results. 30 On the other hand, our patients had advanced disease as demonstrated by the large LV volumes, low LVEF and high pulmonary capillary wedge pressures at baseline. It is thus tempting to assume that the favorable prognosis observed in our patients is due to the tight adherence to current HF therapy guidelines. Ninety-eight percent of our patients received inhibitors of the reninangiotensin axis, and 99 % received beta blocker therapy at a mean dose equipotent to that obtained in the MERIT-HF trial, i.e. approximately 75 % of the evidence-based target dose. We implanted cardiac devices according to current guidelines, but many of our patients improved rapidly and the indications for device implantation were no longer fulfilled. Only 1 of our patients died suddenly.
We present data from a well characterized, thoroughly examined, prospective cohort subjected to meticulous follow-up and little loss of data. The limited number of patients and strict inclusion criteria, including the exclusion of patients on inotropic or mechanical support at enrolment, must be acknowledged before broad generalizations to an unselected population of patients with IDC are made. The label "dilated cardiomyopathy" covers a very heterogeneous group of diseases, as far as both etiology and clinical manifestations are concerned. Thus, a very fastidious characterization and reporting of the actual sample at hand is required for the results to be reproducible, and a direct comparison with historic cohorts must be made with care. 
